{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:12:42Z","timestamp":1788174762141,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007928","name":"Ningbo Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["2016C51011"],"award-info":[{"award-number":["2016C51011"]}],"id":[{"id":"10.13039\/501100007928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003847","name":"Ningbo Municipal Peoples Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jfma.2021.10.015","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T08:54:09Z","timestamp":1635843249000},"page":"1488-1494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device"],"prefix":"10.1016","volume":"121","author":[{"given":"Guohua","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2791-6831","authenticated-orcid":false,"given":"Huimin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2021.10.015_bib1","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2021.10.015_bib2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCULATIONAHA.112.114389","article-title":"Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation 2.3-year follow-up of the PROTECT AF (Watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial","volume":"127","author":"Reddy","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2021.10.015_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial","volume":"64","author":"Holmes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2021.10.015_bib4","doi-asserted-by":"crossref","first-page":"22S","DOI":"10.1378\/chest.119.1_suppl.22S","article-title":"Managing oral anticoagulant therapy","volume":"119","author":"Ansell","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.jfma.2021.10.015_bib5","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1378\/chest.119.1_suppl.8S","article-title":"Oral anticoagulants mechanism of action, clinical effectiveness, and optimal therapeutic range","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2021.10.015_bib6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0049-3848(03)00250-0","article-title":"Current anticoagulant therapy - unmet clinical needs","volume":"109","author":"Hirsh","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.jfma.2021.10.015_bib7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-121-9-199411010-00009","article-title":"Interactions of warfarin with drugs and food","volume":"121","author":"Wells","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2021.10.015_bib8","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","article-title":"The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy","volume":"126","author":"Ansell","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jfma.2021.10.015_bib9","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1177\/0091270006286904","article-title":"Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct Factor Xa inhibitor, in healthy subjects","volume":"46","author":"Kubitza","year":"2006","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jfma.2021.10.015_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.hrthm.2016.10.020","article-title":"Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device","volume":"14","author":"Enomoto","year":"2017","journal-title":"Heart Rhythm"},{"issue":"7","key":"10.1016\/j.jfma.2021.10.015_bib11","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4244\/EIJ-D-17-00042","article-title":"Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry","volume":"13","author":"Martin","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jfma.2021.10.015_bib12","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"29","author":"Gerhard","year":"2020","journal-title":"Eur Heart J"},{"issue":"19","key":"10.1016\/j.jfma.2021.10.015_bib13","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/eurheartj\/ehy807","article-title":"Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial","volume":"40","author":"Chao","year":"2019","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jfma.2021.10.015_bib14","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. Warfarin in Japanese patients with atrial fibrillation\u2013 the J-ROCKET AF study","volume":"76","author":"Masatsugu","year":"2012","journal-title":"Circ J"},{"issue":"suppl_4","key":"10.1016\/j.jfma.2021.10.015_bib15","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/europace\/eux247","article-title":"Optimal dose of dabigatran for the prevention of thromboembolism with minimal bleeding risk in Korean patients with atrial fibrillation","volume":"19","author":"Ki","year":"2017","journal-title":"Europace"},{"issue":"4","key":"10.1016\/j.jfma.2021.10.015_bib16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1373\/clinchem.2006.077180","article-title":"Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values","volume":"53","author":"Levey","year":"2007","journal-title":"Clin Chem"},{"issue":"5","key":"10.1016\/j.jfma.2021.10.015_bib17","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ahj.2006.02.005","article-title":"The PROTECT AF (WATCHMAN left atrial appendage system for embolic PROTECTion in patients with atrial fibrillation) trial","volume":"151","author":"Fountain","year":"2006","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.jfma.2021.10.015_bib18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemostasis"},{"issue":"9","key":"10.1016\/j.jfma.2021.10.015_bib19","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.hrthm.2017.05.038","article-title":"Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial","volume":"14","author":"Boersma","year":"2017","journal-title":"Heart Rhythm"},{"issue":"3","key":"10.1016\/j.jfma.2021.10.015_bib20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1023\/B:THRO.0000011377.78585.63","article-title":"Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range","volume":"15","author":"Schmitt","year":"2003","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"10.1016\/j.jfma.2021.10.015_bib21","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1378\/chest.13-0054","article-title":"Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT\u2082R\u2082 score","volume":"144","author":"Apostolakis","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jfma.2021.10.015_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.110.976449","article-title":"Safety of percutaneous left atrial appendage closure: results from the watchman left atrial appendage system for embolic protection in patients with AF (PROTECT AF) clinical trial and the continued access registry","volume":"123","author":"Reddy","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2021.10.015_bib23","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.amjcard.2016.01.039","article-title":"Assessment of device-related thrombus and associated clinical outcomes with the WATCHMAN left atrial appendage closure device for embolic protection in patients with atrial fibrillation (from the PROTECT-AF Trial)","volume":"117","author":"Main","year":"2016","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.jfma.2021.10.015_bib24","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1016\/j.hrthm.2020.07.022","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation","volume":"17","author":"Chan","year":"2020","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.jfma.2021.10.015_bib25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2133\/dmpk.DMPK-12-RG-034","article-title":"Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation","volume":"28","author":"Tanigawa","year":"2013","journal-title":"Drug Metabol Pharmacokinet"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621004873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664621004873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:47:57Z","timestamp":1760539677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664621004873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0929664621004873"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2021.10.015","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2021.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}